Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
Angiozyme
National Institutes of Health
Create Alert
Related topics
Related topics
3 relations
Broader (2)
Catalytic RNA
anti-FLT-1 ribozyme
Narrower (1)
Ribozyme RPI.4610
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer
P. Morrow
,
R. Murthy
,
+7 authors
G. Hortobagyi
Cancer
2012
Corpus ID: 205664965
Serum and plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis in patients with metastatic breast…
Expand
Highly Cited
2005
Highly Cited
2005
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors
D. Weng
,
P. Masci
,
+10 authors
E. Borden
Molecular Cancer Therapeutics
2005
Corpus ID: 45537551
Purpose: This study intended to determine the maximum tolerated dose, safety, pharmacokinetic variables, clinical response, and…
Expand
2004
2004
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
H. Kobayashi
,
S. Gail Eckhardt
,
+9 authors
M. Basche
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 13212090
PurposeRPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. The…
Expand
Review
2001
Review
2001
Angiozyme: A Novel angiogenesis inhibitor
D. Weng
,
N. Usman
Current oncology reports
2001
Corpus ID: 45576270
Several inhibitors of angiogenesis are being developed for the treatment of cancer. One dominant strategy involves disruption of…
Expand
Review
2000
Review
2000
Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.
N. Usman
,
L. Blatt
The Journal of clinical investigation
2000
Corpus ID: 6607110
The discovery of ribozymes by Cech and Altman has fundamentally changed the view of the function of RNA in chemistry, biology…
Expand
2000
2000
Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.
J. A. Sandberg
,
C. Sproul
,
+8 authors
L. Blatt
Antisense & nucleic acid drug development
2000
Corpus ID: 29194737
The potential acute toxicity of a ribozyme (ANGIOZYME) targeting the flt-1 vascular endothelial growth factor (VEGF) receptor…
Expand
2000
2000
Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens.
T. J. Parry
,
K. Bouhana
,
K. S. Blanchard
,
P. Pavco
,
J. A. Sandberg
Current issues in molecular biology
2000
Corpus ID: 87966
A significant amount of research has been devoted to the chemical stabilization of synthetic ribozymes, in part, so that…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE